Vote Scores

Home / Companies / Inhibikase Therapeutics, Inc. / 26 Jun 2026

Meeting · year to 30 June 2026134 filers reporting

Inhibikase Therapeutics, Inc.: meeting of 26 Jun 2026

Votes reported on Form N-PX, item by item

134 Form N-PX filers reported votes at the Inhibikase Therapeutics, Inc. meeting of 26 Jun 2026. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

2 nominees; 46.1% of reported votes for; 37 filers withheld from or voted against at least one nominee.

178 vote records from 48 filers. 16 of the 48 filers that marked the item either way voted against management.

33.3% for0.0% against66.7% other33.3% against management48 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

213 vote records from 131 filers. 95 of the 124 filers that marked the item either way voted against management. 7 filers reported this item without a management mark.

21.4% for72.5% against6.1% other76.6% against management131 filers66.6% for33.2% against0.1% other33.4% against management66,493,284 reported shares
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 116 filers; for: 5 filers; not applicable: 2 filers; against: 1 filer; 1-year: 1 filer; abstain: 1 filer.

199 vote records from 130 filers. 0 of the 124 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.

3.8% for0.0% against96.2% other0.0% against management130 filers14.2% for0.1% against85.7% other0.1% against management64,971,895 reported shares
4

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

85 vote records from 48 filers. 0 of the 48 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management48 filers100.0% for0.0% against0.0% against management5,403,337 reported shares
5

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

90 vote records from 49 filers. 45 of the 49 filers that marked the item either way voted against management.

4.1% for95.9% against91.8% against management49 filers59.2% for40.8% against40.8% against management13,130,335 reported shares, counted once per item in this group
6

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

77 vote records from 44 filers. 4 of the 44 filers that marked the item either way voted against management.

88.6% for11.4% against9.1% against management44 filers96.6% for3.4% against3.3% against management2,923,063 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Pay-vote frequency4. Auditor
VanguardForAgainst *Split or no voteFor
BlackRock and iSharesForAgainst *Split or no voteFor
FidelityAbstain or withhold *Against *Split or no voteFor
State Street and SPDRSplit or no voteAgainst *Split or no voteFor
American CenturyAbstain or withhold *Against *Split or no voteFor
InvescoNo reportAgainst *Split or no voteNo report
EquitableSplit or no voteAgainst *Split or no voteFor
Charles SchwabForAgainst *Split or no voteFor
Nuveen and TIAASplit or no voteAgainst *Split or no voteFor
ProShares and ProFundsAbstain or withhold *Against *Split or no voteFor
John Hancock and ManulifeAbstain or withhold *Against *Split or no voteFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *Against *Split or no voteFor
J.P. MorganForForSplit or no voteFor
Goldman SachsForForSplit or no voteFor
PGIM and PrudentialNo reportAgainst *Split or no voteNo report
Northern Trust and FlexSharesSplit or no voteAgainst *Split or no voteFor
SEIForAgainst *Split or no voteFor
T. Rowe PriceAbstain or withhold *Against *Split or no voteFor
Lincoln FinancialSplit or no voteAgainst *Split or no voteFor
VoyaForForSplit or no voteFor
Russell InvestmentsNo reportAgainst *Split or no voteNo report
NationwideSplit or no voteAgainst *Split or no voteFor
Victory CapitalAbstain or withhold *Against *Split or no voteFor
Brighthouse FundsForForForFor
Guggenheim and RydexAbstain or withhold *Against *Split or no voteFor
BNY MellonNo reportForSplit or no voteNo report
PrincipalAbstain or withhold *Against *Split or no voteFor
Pacific Life fundsSplit or no voteAgainst *Split or no voteFor
Global XForAgainst *Split or no voteFor
AllianceBernsteinNo reportAgainst *Split or no voteNo report
DWSAbstain or withhold *Against *Split or no voteFor
Neuberger BermanNo reportAgainst *Split or no voteNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Inhibikase Therapeutics, Inc. meeting?

134 Form N-PX filers reported votes at the meeting of 26 Jun 2026. On say-on-pay, 95 of 124 voted against management (76.6%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Inhibikase Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Inhibikase Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Inhibikase Therapeutics, Inc. with a meeting date within three days of 26 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.